What is the Purpose of this Study?
This study focuses on people with newly diagnosed squamous or non-squamous, non-small cell lung cancer that has spread to other areas of the body. The purpose of the study is to evaluate the effectiveness and safety of an experimental drug called ivonescimab compared to another drug, pembrolizumab. Both treatment options will be combined with chemotherapy drugs. For patients with squamous type disease, the chemotherapy drug will be carboplatin and either paclitaxel or nab-paclitaxel. For those with non-squamous type disease, the chemotherapy drug carboplatin and pemetrexed. The study drug (ivonescimab) is an antibody. Antibodies are substances that occur naturally in the body and help fight infection. Ivonescimab blocks 2 proteins in the body that help cancer cells live, grow, and spread. It is possible that the drug may slow the growth and spread of cancer cells.
Eligibility
- * Age ≥ 18 years old at the time of enrollment
- * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- * Expected life expectancy ≥ 3 months
- * Metastatic (Stage IV) NSCLC
Where can I participate?
- CS Cancer Tarzana : Maria Tarallo
- CS Cancer at Beverly Hills : Maria Tarallo
- CS Cancer at Cedars-Sinai Medical Center : Maria Tarallo
- CS Cancer at The Angeles Clinic and Research Institute : Maria Tarallo
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer
More about this Clinical Trial
What is the full name of this clinical trial?
SMT112-3003: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer